Industry News, News

Novo Nordisk Settles Two Lawsuits Over Copycat Versions of Ozempic and Wegovy

February 15, 2024
Gavel and stethoscope

Novo Nordisk said Friday it settled two lawsuits against two businesses claiming to offer compounded versions of its blockbuster drugs Ozempic and Wegovy.

The drugmaker has filed a total of 12 lawsuits against clinics, med spas and compounding pharmacies in the U.S. that claim to offer semaglutide, the active ingredient in Ozempic and Wegovy.

Novo Nordisk holds the patent on semaglutide, and the drugmaker does not supply the ingredient to outside groups, leaving some experts wondering what exactly is being sold to consumers.

The two businesses in the settlements are permanently banned from claiming that their compounded drugs are medicines approved by the Food and Drug Administration, according to Novo Nordisk.

Read more at NBC News >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Bill Regulating Indiana Med Spas Has Passed: What You Need to Know and Why Collective Advocacy Matters
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor